The trademark application LYCIA THERAPEUTICS was filed by Lycia Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on November 14, 2021, and it was registered by office on February 21, 2022 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Change of name and professional address of the trademark registration was recorded on August 6, 2024.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations comprising small molecules and antibodies for degrading disease-causing cellular proteins for treatment of cancer, autoimmune diseases, immunologic-based diseases and other human diseases
Pharmaceutical preparations for the prevention and treatment of cancer, autoimmune diseases, immunologic-based diseases and other human diseases
Biological preparations for the prevention and treatment of cancer, autoimmune diseases, immunologic-based diseases and other human diseases
Gene therapy products, namely, biological preparations for the treatment of cancer, autoimmune diseases, immunologic-based diseases and other human diseases
Pharmaceutical preparations for use in gene therapy
Biological preparations for use in gene therapy
Viruses for therapeutic purposes, namely, for gene therapy and antivirals.
The mark was filed in class 42 with Research and development services in the field of pharmaceuticals.
The mark was filed in class 44 with following description of goods:
Providing medical information
Providing medical information via a website
Medical services
Medical diagnostic testing, medical clinics, medical screenings, medical examinations and medical treatment services
Provision of pharmaceutical information
Pharmaceutical services, consultations and advice.